

Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/Incn20>

Synthesis of the Fully Protected Phosphoramidite of the Benzene-DNA Adduct, N²-(4-Hydroxyphenyl)-2'-Deoxyguanosine and Incorporation of the Later into DNA Oligomers

Ahmed Chenna^a, Ramesh C. Gupta^b, Radha R. Bonala^b, Francis Johnson^b & Bo Hang^c

^a Monogram Biosciences Inc., South San Francisco, California, USA

^b Chem-Master International Inc., Stony Brook, New York, USA

^c Department of Genome Stability, Life Sciences Division, Lawrence Berkeley National Laboratory, University of California, Berkeley, California, USA

Published online: 11 Aug 2008.

To cite this article: Ahmed Chenna, Ramesh C. Gupta, Radha R. Bonala, Francis Johnson & Bo Hang (2008) Synthesis of the Fully Protected Phosphoramidite of the Benzene-DNA Adduct, N²-(4-Hydroxyphenyl)-2'-Deoxyguanosine and Incorporation of the Later into DNA Oligomers, *Nucleosides, Nucleotides and Nucleic Acids*, 27:8, 979-991

To link to this article: <http://dx.doi.org/10.1080/15257770802258034>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

SYNTHESIS OF THE FULLY PROTECTED PHOSPHORAMIDITE OF THE BENZENE-DNA ADDUCT, N^2 -(4-HYDROXYPHENYL)-2'-DEOXYGUANOSINE AND INCORPORATION OF THE LATER INTO DNA OLIGOMERS

Ahmed Chenna,¹ Ramesh C. Gupta,² Radha R. Bonala,² Francis Johnson,² and Bo Hang³

¹Monogram Biosciences Inc., South San Francisco, California, USA

²Chem-Master International Inc., Stony Brook, New York, USA

³Department of Genome Stability, Life Sciences Division, Lawrence Berkeley National Laboratory, University of California, Berkeley, California, USA

□ N^2 -(4-Hydroxyphenyl)-2'-deoxyguanosine-5'-O-DMT-3'-phosphoramidite has been synthesized and used to incorporate the N^2 -(4-hydroxyphenyl)-2'-dG (N^2 -4-HOPh-dG) into DNA, using solid-state synthesis technology. The key step to obtaining the xenonucleoside is a palladium (Xantphos-chelated) catalyzed N^2 -arylation (Buchwald-Hartwig reaction) of a fully protected 2'-deoxyguanosine derivative by 4-isobutyryloxybromobenzene. The reaction proceeded in good yield and the adduct was converted to the required 5'-O-DMT-3'-O-phosphoramidite by standard methods. The latter was used to synthesize oligodeoxynucleotides in which the N^2 -4-HOPh-dG adduct was incorporated site-specifically. The oligomers were purified by reverse-phase HPLC. Enzymatic hydrolysis and HPLC analysis confirmed the presence of this adduct in the oligomers.

Keywords Benzene DNA adduct; hydroquinone; *p*-benzoquinone; buchwald-hartwig reaction; N^2 -(4-hydroxyphenyl)-2'-deoxyguanosine

INTRODUCTION

Humans are exposed to benzene from different sources such as automobile exhaust fumes, cigarette smoke and in industries involved in rubber manufacture, crude oil, gasoline, and chemical manufacturing. Benzene has been linked to a number of chronic conditions of the haematopoietic system

Received 12 December 2007; accepted 8 April 2008.

This work was supported by NIH grant CA72079 (to B. H.) and was administrated by the Lawrence Berkeley National Laboratory under Department of Energy contract DE-AC03-76SF00098.

Address correspondence to Bo Hang, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA94720. E-mail: Bo_hang@lbl.gov

of exposed individuals, due to its metabolism in the liver and bone marrow, to more reactive species.^[1] These chronic effects include leucopenia, thrombocytopenia, pancytopenia, anemia, and myelodysplastic syndrome. More importantly, benzene is a recognized human leukemogen.^[2,3] Several epidemiologic studies have established a relationship between occupational exposure to benzene and human leukemia, especially acute myelogenous leukemia (AML).^[4,5]

Inhaled benzene is first metabolized in the liver, where it is converted by cytochrome P450-2E1 to benzene oxide, then to phenol, hydroquinone (HQ), and other phenolic metabolites.^[6,7] These compounds may travel to the bone marrow, the main target organ of benzene, where they are oxidized to genotoxic quinones such as *p*-benzoquinone (*p*-BQ) and *o*-BQ by the high levels of myeloperoxidase (MPO) in this tissue (Figure 1). The mutagenic potential of benzene and its major metabolites such as HQ and *p*-BQ has been extensively investigated.^[8] Studies using mammalian systems have shown that benzene metabolites induce base substitution and deletion in various cell lines, animal tissues, and blood from exposed individuals.^[8]

The precise mechanisms underlying the benzene-induced mutagenesis remain poorly understood. There are numerous reports dealing with the detection of covalent DNA adducts by HQ and *p*-BQ in vitro.^[8,9] These two compounds are stable metabolites derived from benzene, and *p*-BQ is also present in a number of drugs and chemical substances.^[10–12] Both metabolites form exocyclic benzetheno adducts with dG, dA and dC.^[13–17] Although they were not detected in tissues such as the bone marrow by ³²P-postlabeling,^[18,19] their in vivo formation by similar mechanisms to those seen in in vitro reactions is expected, given that the yields of these adducts were high in the latter. Using site-directed mutagenesis, we recently showed that all three *p*-BQ adducts are highly mutagenic in *Saccharomyces cerevisiae* by predominantly causing deletion mutations.^[20] We have also shown that these *p*-BQ adducts, when present in DNA, are substrates for human apurinic/apyrimidinic (AP) endonuclease (APE1), which directly incises the phosphodiester bond 5' to the adduct.^[21–24]

Although benzene-derived DNA adducts have been identified in vitro, the in vivo detection of such adducts has been a subject of controversy. Using ³²P-postlabeling, Bauer et al. showed the formation of several DNA adducts in the livers of rabbits treated with benzene.^[25] Later, the Bodell group discovered in vivo adducts in a human promyelocytic (HL-60) cell line^[18,26] and bone marrow of mice^[19] that were treated with benzene, HQ, or *p*-BQ. They found that the DNA adducts formed after benzene administration in mouse bone marrow are identical to those produced in HL-60 or mouse bone marrow cells treated with HQ or *p*-BQ. Moreover, the observed induction of toxicity in the bone marrow was paralleled by formation of DNA adducts.^[19] By ³²P-postlabeling, the principal adduct found in the cells targeted by benzene has the same chromatographic





FIGURE 1 The metabolic route from benzene to the formation of HQ and *p*-BQ. These two stable metabolites may react with guanine in the bone marrow to form N^2 -(4-hydroxyphenyl)-2'-deoxyguanosine (N^2 -4-HOPh-dG).

properties as N^2 -(4-hydroxyphenyl)-2'-deoxyguanosine-3'-phosphate.^[18,26] This adduct can also be formed in vitro by allowing guanosine 3'-phosphate to react with *p*-BQ.^[18,26] To date, the biochemical properties and biological importance of this adduct await investigation.

In order to understand the molecular mechanism by which HQ and *p*-BQ exert their mutagenic effects, it is important to study their principal adduct formed in vivo, N^2 -(4-hydroxyphenyl)-2'-deoxyguanosine (N^2 -4-HOPh-dG), regarding its potential effects on DNA replication and repair. Such studies would be greatly facilitated with oligonucleotides containing a site-specific adduct. Previously, we have synthesized the phosphoramidites of exocyclic *p*-BQ-dA, *p*-BQ-dC and one of the *p*-BQ-dG adducts and incorporated them site-specifically into oligomeric DNA.^[27,28] In this work, we report for the first time the synthesis of N^2 -4-HOPh-dG-phosphoramidite and its incorporation into defined DNA oligonucleotides.

RESULTS AND DISCUSSION

Previously, Pongracz and Bodell^[26] reported the synthesis of N^2 -(4-hydroxyphenyl)-2'-deoxyguanosine-3'-phosphate as the 3'-phosphate. We have now successfully synthesized the fully-protected N^2 -(4-hydroxyphenyl)-2'-deoxyguanosine-3'-phosphoramidite **7**, by a completely new method (Scheme 1), which gave better yields. Our approach is similar to that used previously for the synthesis and incorporation of the 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) adducts into DNA in which the key procedure is a Buchwald-Hartwig (BH) reaction.^[29,30] Compound **1** when coupled with 4-isobutyryloxybromobenzene **2** under the conditions of the Buchwald-Hartwig reaction gave compound **3** in 80% yield. Removal of the 6-*O*-benzyl group from the purine moiety was then accomplished by hydrogenolysis over a palladium catalyst to give compound **4**, which, after purification by column chromatography, was obtained in 88% yield. The silyl protecting groups of compound **4** were removed by HF in pyridine, to give compound **5** in 76% yield after purification. The electrospray mass spectrum of this compound showed an intense protonated molecular ion at m/z 430 ($M+H$)⁺ and the natriated species at m/z at 452 ($M + Na$)⁺ (Figure 2). Reaction of compound **5** with DMT-Cl in pyridine produced compound **6** in 90% yield, which was then allowed to react with (2-cyanoethoxy)-bis(*N,N*-diisopropylamino)phosphane to produce the fully protected phosphoramidite compound **7**. All of the above compounds were identified by MS, ¹H NMR, ¹³C NMR and in the case of compound **7**, ³¹P NMR analysis was used as well. (See ¹H NMR of **7** in Figure 3.) The latter was then used to introduce the xenonucleoside into defined oligonucleotides by DNA synthesizer. The composition of the oligomers was confirmed after enzymatic digestion of the DNA oligomers to nucleosides, followed



SCHEME 1 The synthesis of the fully protected *N*²-(4-hydroxyphenyl)-2'-deoxyguanosine-3'-phosphoramidite 7.

by HPLC analysis, which showed that the *N*²-4-HOPh-dG residual survived the conditions used in the DNA synthesis and the deprotection procedure (Figure 4). Based on the calculation of the integrated area of each HPLC peak of the nucleosides and the modified base (Figure 4) and by using the extinction coefficient for each nucleoside, we found that the 40-mer contains 9.9 dC, 9.4 dG, 12.4 T, 7.4 dA, and 0.9 *N*²-4-HOPh-dG. The actual composition of the 40-mer is 10 dC, 9 dG, 12 T, 8 dA, and 1 *N*²-4-HOPh-dG.




FIGURE 2 Electrospray mass spectrum of *N*²-4-HOPh-dG (5).

The biochemical work is underway to evaluate the mutagenic potential of this adduct as well as possible repair mechanisms that acts on it using these oligonucleotides.

EXPERIMENTAL

(*Caution:* The organic solvents used in this work should be stored and used in a well-ventilated hood.)

Chemicals and Reagents

All reagents and solvents employed were of commercial grade and were used as such, unless otherwise specified. NMR (¹H and ¹³C) spectra were recorded on a Gemini 300 spectrometer. Samples prepared for NMR analysis were dissolved in CDCl₃ or DMSO-d₆. Chemical shifts are reported in ppm relative to TMS in the proton spectra and to the deuterated solvent in the carbon spectra. Mass spectra were recorded on a Micromass Trio in fast atom bombardment (FAB) mode. Thin-layer chromatography




FIGURE 3 ¹H NMR of *N*²-(4-hydroxyphenyl)-2'-deoxyguanosine-3'-phosphoramidite (7).

(TLC) was performed on silica gel sheets (riedel-deHaën, Sleeze, Germany) containing a fluorescent indicator. Components were visualized by UV light ($\lambda = 254$ nm) or by spraying with a solution of phosphomolybdic acid. Flash column chromatography separations were carried out on 60 Å (230–400 mesh) silica gel (Silica-P Flash Silica Gel obtained from Silicycle, Quebec, QC, Canada). All experiments dealing with moisture or air-sensitive compounds were conducted under dry nitrogen. The starting materials and reagents, unless otherwise specified, were the best commercial grades available (Aldrich, Fluka) and were used without further purification. After purification all new products showed a single spot on TLC analysis.

HPLC

Solvent systems included acetonitrile (solvent A), triethylammonium acetate (0.1 M, pH 7.0, solvent B), and potassium phosphate buffer (0.01 M, pH 4.5, solvent C). System 1: Oligonucleotides were purified using a PRP-1-C18 column (305 × 7 mm, 10 μ m, Hamilton Corp.). The initial concentration of solvent A was 10% and solvent B was 90%, then solvent A was increased linearly to 38% over 40 minutes at a flow rate of 3 ml/minute. System 2: This was used for the analysis of the enzyme digest of the oligonucleotides and was performed with a Supelcosil LC-18-DB column




FIGURE 4 A) HPLC profile of 2'-deoxynucleosides obtained as a result of enzymatic digestion of the N^2 -4-HOPh-dG-containing 40-mer. B) HPLC profile of N^2 -4-HOPh-dG.

(25 \times 0.46 cm, 5 μ m, Supelco Inc.) using 0% solvent A, 100% solvent C at start. Solvent A was linearly increased to 12% over 30 minutes, then to 40% over 15 minutes where it was held for 10 minutes at a flow rate of 1 ml/minute. The HPLC instrument was an Agilent 1100 series.

Ultraviolet spectra were recorded on an Agilent 8453 spectrophotometer using 0.2 cm cuvette. TLC was performed on silica gel 60, F254 plates.

Column chromatography was performed using silica gel 60 with elution under pressure.

Chemical Syntheses (Scheme 1)

*N*²-(4-Isobutyryloxyphenyl)-*O*⁶-benzyl-3',5'-bis-*O*-(*tert*-butyldimethylsilyl)-2'-deoxyguanosine (**3**)

An oven-dried 100 mL two-necked round-bottomed flask was charged with the protected purine nucleoside **1**^[31] (1.17 g, 2 mmol), cesium carbonate (0.92 g, 2.8 mmol), Pd₂(dba)₃ (230 mg, 0.25 mmol), xantphos (480 mg, 0.8 mmol), 4-isobutyryloxybromobenzene (**2**, 0.724 g, 2.98 mmol) and toluene (15 mL) under a nitrogen atmosphere. This mixture was stirred for 30 minutes at room temperature, later heated at 80°C for 6 hours. It was cooled to room temperature, the solids were filtered, and the solid cake was washed with ethyl acetate. The filtrate was evaporated to dryness and the residue was purified by silica gel column chromatography using CH₂Cl₂:ethyl acetate (98:2) as the eluant to give pure **3** (1.2 g, 80%). ¹H NMR (CDCl₃): δ 8.09 (s, 1H), 7.67 (d, 2H), 7.55 (m, 2H), 7.45–7.33 (m, 3H), 7.28 (br s, 1H), 7.09 (d, 2H), 6.46 (t, 1H), 5.68 (s, 2H), 4.64 (m, 1H), 4.08 (m, 1H), 3.88–3.85 (m, 2H), 2.87 (m, 1H), 2.72–2.39 (m, 2H), 1.40 (s, 3H), 1.38 (s, 3H), 0.98 (s, 9H), 0.97 (s, 9H), 0.16 (s, 6H), 0.15 (s, 6H). ¹³C NMR (CDCl₃): δ 175.43, 160.15, 155.26, 152.81, 145.11, 137.79, 137.35, 136.08, 128.03, 127.68, 127.60, 121.24, 119.37, 116.09, 87.35, 83.61, 77.42, 77.00, 76.57, 71.64, 67.79, 62.53, 41.01, 33.80, 25.68, 25.47, 18.67, 18.09, 17.67, –4.94, –5.06, –5.66, –5.77. ESI (M + H) 748.

*N*²-(4-Isobutyryloxyphenyl)-3',5'-bis-*O*-(*tert*-butyldimethylsilyl)-2'-deoxyguanosine (**4**)

To a solution of **3** (1.2 g, 1.6 mmol) in ethyl acetate (50 mL) was added a 10% palladium-on-carbon (150 mg) catalyst. The flask was evacuated (50 Torr) and flushed with hydrogen three times. The mixture was shaken under hydrogen for 16 hours at 50 psi, filtered through a pad of Celite to remove the catalyst, and then concentrated under reduced pressure. The residue was purified by column chromatography using 3% methanol in methylene chloride to obtain the pure debenzylated product **4** as a glassy solid (0.930 gm 88%). ¹H NMR (CDCl₃): δ 11.76 (br s, 1H), 9.75 (br s, 1H), 8.14 (d, 2H), 8.09 (s, 1H), 7.10 (d, 2H), 6.41 (t, 1H), 4.63 (m, 1H), 4.07 (m, 2H), 2.87 (m, 1H), 2.52 (m, 2H), 1.40 (s, 3H), 1.38 (s, 3H), 1.00 (s, 9H), 0.98 (s, 9H), 0.18 (s, 6H), 0.16 (s, 1H). ¹³C NMR (CDCl₃): δ 175.54, 158.83, 150.62, 149.57, 146.05, 136.46, 136.31, 121.33, 121.02, 118.16, 87.64, 84.04, 71.76, 62.75, 41.71, 34.09, 25.92, 25.71, 18.94, 18.35, 17.90, –4.68, –4.82, –5.41, –5.53. ESI (M + H) 658.

*Preparation of N*²-(4-isobutyryloxyphenyl)-2'-deoxyguanosine (**5**). To an ice-cold solution of **4** (0.9 g, 1.37 mmol) in pyridine (20 mL) was added HF/Py

(2.2 mL, 70% of HF in Py from Aldrich Chemical Co.) over a period of 3 minutes. The mixture was stirred at room temperature overnight, then poured into ice-cold water (100 mL) containing NaHCO₃ (6.5 g) and stirred for 2 hours. The reaction mixture was evaporated to dryness and co-evaporated with methanol three times and the residual material was adsorbed onto silica gel using methanol as a solvent. It was purified by silica gel using 15% methanol in methylene chloride to obtain the pure **5** as a white solid (450 mg, 76%). ¹H NMR (DMSO-d₆): δ 10.67 (br s, 1H), 9.01 (s, 1H), 8.03 (s, 1H), 7.61 (d, 2H), 7.09 (d, 2H), 6.195 (t, 1H), 5.27 (br s, 1H), 4.89 (br s, 1H), 3.81 (m, 1H), 3.50 (m, 2H), 2.78 (m, 1H), 2.59 (m, 1H), 2.28 (m, 1H), 1.22 (s, 3H), 1.20 (s, 3H). ¹³C NMR (DMSO-d₆): δ 175.96, 157.14, 150.09, 149.97, 146.32, 137.18, 122.73, 120.95, 118.97, 88.35, 83.64, 71.31, 62.29, 33.97, 19.38. ESI (M+H) 429.

***N*²-(4-Isobutyryloxyphenyl)-5'-O-(4,4'-dimethoxytrityl)-2'-deoxyguanosine (6)**

To a solution of **5** (0.428 g, 1 mmol) in pyridine (15 mL) was added DMT chloride (0.440 g, 1.3 mmol) as a solid and the mixture was stirred at room temperature for 3 hours. TLC (CH₂Cl₂: MeOH: 85:15) of the mixture showed the reaction to be ~90% complete. The reaction was quenched by adding methanol (5 mL) and the mixture was stirred for 30 minutes at room temperature, and then concentrated under reduced pressure. To the residue was added aqueous NaHCO₃ (25 mL) and the mixture was extracted with methylene chloride. The methylene chloride extract was dried over anhydrous MgSO₄, filtered, and concentrated. The crude product was purified by column chromatography using TEA-treated silica gel and CH₂Cl₂: MeOH (95:5) as the eluant to give pure **6** (550 mg, 90% yield based on consumed starting material). The column was further eluted with 15% methanol in methylene chloride to recover the unreacted starting material (70 mg). ¹H NMR (CDCl₃): δ 10.01 (br s, 1H), 7.75 (s, 1H), 7.58 (d, 2H), 7.41–7.16 (m, 10H), 6.89 (d, 2H), 6.79 (d, 4H), 6.15 (t, 1H), 4.46 (m, 1H), 4.05 (m, 1H), 3.73 (s, 6H), 3.27 (m, 2H), 2.84 (m, 1H), 2.72 (m, 1H), 2.41 (m, 1H). ¹³C NMR (CDCl₃): δ 176.51, 158.38, 150.19, 149.95, 146.30, 144.68, 136.73, 135.90, 135.86, 129.95, 128.13, 127.69, 126.71, 123.31, 121.49, 118.59, 113.00, 86.23, 85.61, 83.98, 71.44, 64.25, 55.09, 39.52, 34.07, 18.83. ESI (M+H) 732.

***N*²-(4-Isobutyryloxyphenyl)-5'-O-(4,4'-dimethoxytrityl)-3'-O-[N,N-diisopropylamino-(2-cyanoethoxy)-phosphinyl]-2'-deoxyguanosine (7)**

Compound **6** (256 mg, 0.35 mmol) was co-evaporated with dry toluene (3 × 10 mL), and the residue was redissolved in dry methylene chloride (10 mL). Tetrazole (28 mg, 0.40 mmole) was then added followed by (2-cyanoethoxy)- bis(N,N-diisopropylamino)phosphane (147 mg, 0.49 mmole). The reaction mixture was stirred at room temperature for 2 hours under nitrogen and then poured into aqueous NaHCO₃ (10%, 10 mL). The

methylene chloride layer was separated and the aqueous layer was extracted once with methylene chloride (20 mL). The combined methylene chloride extract was dried over Na₂SO₄, filtered and concentrated under reduced pressure to obtain the desired crude product **7** as an oil. The crude residue was purified on a silica gel column pretreated with triethylamine, using methylene chloride:acetone (3:2) as the eluant. The fractions containing the pure material were collected and concentrated under reduced pressure and the resulting solid was triturated with isorpropyl ether and filtered to give pure **7** as a white solid (240 mg, 73%). ¹H NMR (CDCl₃): δ 8.76 (br s, 1H), 8.02 (br s, 1H), 8.01 (d, 1H), 7.88 (d, 1H), 7.48–7.25 (m, 10H), 7.02 (d, 2H), 6.85 (m, 4H), 6.41 (t, 1H), 4.71 (m, 1H), 4.34 (m, 1H), 3.80 (s, 6H), 3.65–3.74 (m, 5H), 3.41 (m, 2H), 3.09 (m, 1H), 2.87–2.47 (m, 3H), 1.38–1.16 (m, 18H). ¹³C NMR (CDCl₃): δ 175.62, 158.94, 158.55, 150.92, 149.72, 146.26, 144.52, 136.22, 135.63, 135.53, 130.13, 130.07, 130.02, 128.16, 128.10, 127.85, 126.90, 121.54, 121.26, 118.46, 117.61, 113.16, 86.48, 85.81, 84.15, 74.01, 63.66, 58.40, 58.21, 55.17, 46.13, 43.39, 43.34, 43.27, 43.21, 40.24, 34.12, 24.58, 24.55, 24.51, 20.35, 20.27, 20.18, 18.96. ³¹P NMR (CDCl₃): δ 150.09, 149.60.

Solid-Phase Synthesis of DNA Oligonucleotides

The fully-protected phosphoramidite compound **7** was used to synthesize three different oligonucleotides at the 1 μmole scale: a 22-mer, a 25-mer, and a 40-mer using an Applied Biosystem 394 automated DNA synthesizer by standard phosphoramidite chemistry. Phenoxyacetyl (PAC) was used as the *N*-protecting group in the synthesis of the DNA oligomers. Because amidite **7** has very limited solubility in acetonitrile, dry methylene chloride (100%) was used to dissolve the amidite **7**, which was used in the DNA synthesis. The coupling time for the amidite **7** was increased to 15 minutes, and the coupling efficiency at the *N*²-4-HOPh-dG step was 97% for all oligonucleotides. The overall yields of the oligonucleotides were 86% for the 22-mer, 80% for the 25-mer, and 65% for the 40-mer. The oligonucleotides were then cleaved from the resin and deprotected by means of 28% ammonium hydroxide containing 1% of 2-mercaptoethanol for 2 hours at 65°C. The latter reagent prevents oxidative degradation of the *N*²-4-HOPh-dG lesion. The oligonucleotides were purified by reverse phase HPLC on a C-18 column. The sequences of the DNA oligomers synthesized are as follows:

- 1: 5'-GTAAGCT**X**GATCCTCTAGAGCG-3' (22-mer)
 - 2: 5'-CCGCTA**X**CGGGTACCGAGCTCGAAT-3' (25-mer)
 - 3: 5'-TTGCTTTGTCACCCAGGCT**X**GACTGCAGTGGTACAATCAT-3' (40-mer)
- X** = *N*²-4-HOPh-dG

Enzymatic Digestion of the Oligomers

The composition of the oligomers was confirmed by enzymatic digestion of the DNA oligomers to nucleosides, which were identified by HPLC analysis. A defined oligonucleotide (1.0 A₂₆₀ unit) was dissolved in 44 μ L of deionized water, 0.8 μ L of 1 M MgCl₂, and 3.5 μ L of 0.5 M Tris-HCl buffer (pH 7.5) and digested with snake venom phosphodiesterase (2.5 μ L) and bacterial alkaline phosphatase (4.0 μ L) at 37 °C for 16 hours. The digested mixture was then analyzed on a C-18 reverse-phase HPLC Supelcosil column using solvent system 2 noted above.

REFERENCES

1. NTP Toxicology and Carcinogenesis Studies of Benzene (CAS No. 71-43-2) in F344/N Rats and B6C3F1 Mice (Gavage Studies). *Natl. Toxicol. Program Tech. Rep. Ser.* **1986**, 289, 1–277.
2. IARC. *IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. Some industrial chemicals and dyestuffs*. International Agency for Research on Cancer: Lyon, France, 1982, vol. 29.
3. NTP. *11th Report on carcinogens*. U.S. Department of Health and Human Services, National Toxicology Program, Atlanta, GA, 2005.
4. Yin, S.-N.; Hayes, R.; Linet, M.; Li, G.; Dosemeci, M.; Travis, L.; Zhang, Z.; Li, D.; Chow, W.; Wacholder, S.; Blot, W. Recent studies of human exposure to benzene in China and Europe. An expanded cohort study of cancer among benzene-exposed workers in China. *Environ. Health Perspect.* **1996**, 1339–1341.
5. Glass, D.C.; Gray, C.N.; Jolley, D.J.; Gibbons, C.; Sim, M.R.; Fritschi, L.; Adams, G.G.; Bisby, J.A.; Manuell, R. Leukemia risk associated with low-level benzene exposure. *Epidemiology* **2003**, 14, 569–577.
6. Snyder, R.; Hedli, C.C. An overview of benzene metabolism. *Environ. Health Perspect.* **1996**, 104 (Suppl. 6), 1165–1171.
7. Lovern, M.R.; Cole, C.E.; Schlosser, P.M. A review of quantitative studies of benzene metabolism. *Crit. Rev. Toxicol.* **2001**, 31, 285–311.
8. Whysner, J.; Reddy, M.V.; Ross, P.M.; Mohan, M.; Lax, E.A. Genotoxicity of benzene and its metabolites. *Mutat. Res.* **2004**, 566, 99–130.
9. Exocyclic DNA Adducts in Mutagenesis and Carcinogenesis. Proceedings of the 2nd international conference Heidelberg, Germany, September 1998. *IARC Sci Publ* **1999**, 150, 1–361.
10. Zheng, J.; Hanzlik, R.P. Dihydroxylated mercapturic acid metabolites of bromobenzene. *Chem. Res. Toxicol.* **1992**, 5, 561–567.
11. Pascoe, G.A.; Callemann, C.J.; Baille, T.A. Identification of S-(2,5-dihydroxyphenyl)-cysteine and S-(2,5-dihydroxyphenyl)-N-acetyl-cysteine as urinary metabolites of acetaminophen in the mouse. Evidence for p-benzoquinone as a reactive intermediate in acetaminophen metabolism. *Chem. Biol. Interact.* **1988**, 68, 85–98.
12. McDonald, T.A.; Waidyanatha, S.; Rappaport, S.M. Measurement of adducts of benzoquinone with hemoglobin and albumin. *Carcinogenesis* **1993**, 14, 1927–1932.
13. Jowa, L.; Winkle, S.; Kalf, G.; Witz, G.; Snyder, R. Deoxyguanosine adducts formed from benzoquinone and hydroquinone. *Adv. Exp. Med. Biol.* **1986**, 197, 825–832.
14. Jowa, L.; Witz, G.; Snyder, R.; Winkle, S.; Kalf, G.F. Synthesis and characterization of deoxyguanosine-benzoquinone adducts. *J. Appl. Toxicol.* **1990**, 10, 47–54.
15. Pongracz, K.; Bodell, W.J. Detection of 3'-hydroxy-1,N⁶-benzetheno-2'-deoxyadenosine 3'-phosphate by ³²P postlabeling of DNA reacted with p-benzoquinone. *Chem. Res. Toxicol.* **1991**, 4, 199–202.
16. Pongracz, K.; Kaur, S.; Burlingame, A.L.; Bodell, W.J. Detection of (3'-hydroxy)-3,N⁴-benzetheno-2'-deoxycytidine-3'-phosphate by ³²P-postlabeling of DNA reacted with p-benzoquinone. *Carcinogenesis* **1990**, 11, 1469–1472.
17. Gaskell, M.; Jukes, R.; Jones, D.J.; Martin, E.A.; Farmer, P.B. Identification and characterization of (3'',4''-dihydroxy)-1,N²-benzetheno-2'-deoxyguanosine 3 ϵ -monophosphate, a novel DNA adduct

- formed by benzene metabolites. *Chem. Res. Toxicol.* **2002**, 15, 1088–1095.
18. Levay, G.; Pongracz, K.; Bodell, W.J. Detection of DNA adducts in HL-60 cells treated with hydroquinone and p-benzoquinone by ³²P-postlabeling. *Carcinogenesis* **1991**, 12, 1181–1186.
 19. Bodell, W.J.; Pathak, D.N.; Levay, G.; Ye, Q.; Pongracz, K. Investigation of the DNA adducts formed in B6C3F1 mice treated with benzene: implications for molecular dosimetry. *Environ. Health Perspect.* **1996**, 104 (Suppl. 6), 1189–1193.
 20. Xie, Z.; Zhang, Y.; Guliaev, A.B.; Shen, H.; Hang, B.; Singer, B.; Wang, Z. The p-benzoquinone DNA adducts derived from benzene are highly mutagenic. *DNA Repair (Amst)* **2005**, 4, 1399–1409.
 21. Chenna, A.; Hang, B.; Rydberg, B.; Kim, E.; Pongracz, K.; Bodell, W.J.; Singer, B. The benzene metabolite p-benzoquinone forms adducts with DNA bases that are excised by a repair activity from human cells that differs from an ethenoadenine glycosylase. *Proc. Natl. Acad. Sci. USA* **1995**, 92, 5890–5894.
 22. Hang, B.; Chenna, A.; Fraenkel-Conrat, H.; Singer, B. An unusual mechanism for the major human apurinic/aprimidinic (AP) endonuclease involving 5' cleavage of DNA containing a benzene-derived exocyclic adduct in the absence of an AP site. *Proc. Natl. Acad. Sci. USA* **1996**, 93, 13737–13741.
 23. Hang, B.; Chenna, A.; Sagi, J.; Singer, B. Differential cleavage of oligonucleotides containing the benzene-derived adduct, 1,N⁶-benzetheno-dA, by the major human AP endonuclease HAP1 and *Escherichia coli* exonuclease III and endonuclease IV. *Carcinogenesis* **1998**, 19, 1339–1343.
 24. Guliaev, A.B.; Hang, B.; Singer, B. Structural insights by molecular dynamics simulations into specificity of the major human AP endonuclease toward the benzene-derived DNA adduct, pBQ-C. *Nucleic. Acids. Res.* **2004**, 32, 2844–2852.
 25. Bauer, H.; Dimitriadis, E.A.; Snyder, R. An in vivo study of benzene metabolite DNA adduct formation in liver of male New Zealand rabbits. *Arch. Toxicol.* **1989**, 63, 209–213.
 26. Pongracz, K.; Bodell, W.J. Synthesis of N²-(4-hydroxyphenyl)-2'-deoxyguanosine 3'-phosphate: comparison by ³²P-postlabeling with the DNA adduct formed in HL-60 cells treated with hydroquinone. *Chem. Res. Toxicol.* **1996**, 9, 593–598.
 27. Chenna, A.; Singer, B. Large scale synthesis of p-benzoquinone-2'-deoxycytidine and p-benzoquinone-2'-deoxyadenosine adducts and their site-specific incorporation into DNA oligonucleotides. *Chem. Res. Toxicol.* **1995**, 8, 865–874.
 28. Chenna, A.; Singer, B. Synthesis of a benzene metabolite adduct, 3'-hydroxy-1,N²-benzetheno-2'-deoxyguanosine, and its site-specific incorporation into DNA oligonucleotides. *Chem. Res. Toxicol.* **1997**, 10, 165–171.
 29. Lakshman, M.K. Synthesis of biologically important nucleoside analogs by Palladium-catalyzed C-N bond-formation. *Curr. Org. Synth.* **2005**, 2, 83–112.
 30. Bonala, R.; Torres, M.C.; Iden, C.R.; Johnson, F. Synthesis of the PhIP adduct of 2'-deoxyguanosine and its incorporation into oligomeric DNA. *Chem. Res. Toxicol.* **2006**, 19, 734–738.
 31. Harwood, E.A.; Sigurdsson, S.T.; Edfeldt, N.B.F.; Reid, B.R.; Hopkins, P.B. Synthesis and preliminary structural characterization of nitrous acid interstrand cross-linked duplex DNA. *J. Am. Chem. Soc.* **1999**, 121, 5081–5082.